share_log

Piper Sandler Maintains Overweight on TCR2 Therapeutics, Raises Price Target to $10

Benzinga Real-time News ·  Jan 6, 2023 06:38

Piper Sandler analyst Do Kim maintains TCR2 Therapeutics (NASDAQ:TCRR) with a Overweight and raises the price target from $8 to $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment